Your browser is no longer supported. Please, upgrade your browser.
IKNA [NASD]
Ikena Oncology, Inc.
Index- P/E- EPS (ttm)- Insider Own0.10% Shs Outstand35.85M Perf Week-1.74%
Market Cap456.54M Forward P/E- EPS next Y-1.56 Insider Trans0.00% Shs Float35.83M Perf Month13.87%
Income- PEG- EPS next Q-0.42 Inst Own77.20% Short Float4.23% Perf Quarter-2.26%
Sales9.44M P/S48.36 EPS this Y-163.20% Inst Trans6.93% Short Ratio11.61 Perf Half Y-
Book/sh6.03 P/B2.15 EPS next Y46.90% ROA- Target Price- Perf Year-
Cash/sh7.50 P/C1.73 EPS next 5Y- ROE- 52W Range9.63 - 37.61 Perf YTD-59.47%
Dividend- P/FCF- EPS past 5Y- ROI44.00% 52W High-65.51% Beta-
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low34.68% ATR1.03
Employees33 Current Ratio8.80 Sales Q/Q25.00% Oper. Margin- RSI (14)54.13 Volatility8.69% 8.98%
OptionableNo Debt/Eq0.00 EPS Q/Q-139.50% Profit Margin- Rel Volume1.98 Prev Close13.10
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume130.44K Price12.97
Recom1.50 SMA203.03% SMA509.36% SMA200-18.22% Volume258,372 Change-0.99%
May-05-21Resumed Credit Suisse Outperform $30
Apr-26-21Resumed Credit Suisse Outperform $30
Apr-20-21Initiated William Blair Outperform
Apr-20-21Initiated Jefferies Buy
Apr-20-21Initiated Credit Suisse Outperform $30
Sep-02-21 07:00AM  
Aug-12-21 07:00AM  
Jul-08-21 07:00AM  
Jun-26-21 05:18AM  
May-26-21 07:00AM  
May-13-21 07:00AM  
Apr-15-21 07:00AM  
Mar-30-21 04:05PM  
Mar-25-21 08:55PM  
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.